SLAMF7-directed immunotherapy in MPN
Current understanding
SLAMF7 (CS1/CD319) is a signaling lymphocytic activation molecule family receptor expressed on plasma cells, NK cells, and subsets of myeloid lineage cells, and is the target of elotuzumab, an approved monoclonal antibody in multiple myeloma that engages SLAMF7 on tumor cells and activates NK-cell-mediated ADCC via SLAMF7 on effectors. Its role in MPN biology is largely unexplored, but a phase II trial of elotuzumab in JAK2-mutated myelofibrosis is now probing whether SLAMF7 engagement can deliver disease control, hematologic improvement, and bone marrow remodeling in a JAK-STAT-driven myeloid neoplasm. This represents the first-in-class application of SLAMF7-directed immunotherapy to MPN and an entirely new immunologic mechanism in this disease space.
Evidence log
- 2026-06-24 — Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.: cross-connection with cd4-car-t-cell-therapy-cmml: Both target surface lineage/activation antigens on MPN-spectrum clones — CD4CAR uses engineered T cells against CD4+ CMML monocytic cells, whereas SLAMF7 engagement recruits NK-mediated ADCC, illustrating convergent surface-antigen immunotherapy approaches across MPN subtypes. (novelty: 4)
- 2026-06-11 — Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis: cross-connection with jak-stat-signaling: Elotuzumab targets JAK2-mutated myelofibrosis specifically, testing whether SLAMF7-directed antibody immunotherapy can suppress disease driven by constitutive JAK-STAT activation. (novelty: 4)